FDA to hasten review of Immunomedics' pancreatic cancer drug

02/5/2009 | Forbes

Immunomedics' yttrium-90-labeled hPAM4, a treatment for pancreatic cancer, obtained fast-track designation from the FDA. The drug is undergoing early-stage clinical development.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Principal Engineer - Service (US/MI/00/0043/SL) - 14000009CP
Abbott
Chicago, IL
Senior Manager, Compliance
Stryker
Fremont, CA
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA